Key result
Adalimumab use was temporally associated with fatal acute necrotizing eosinophilic myocarditis in a 51-year-old woman with relapsing polychondritis.
Why the study?
Is adalimumab associated with acute necrotizing eosinophilic myocarditis in patients with relapsing polychondritis?
Case Report (n=1)
Is adalimumab associated with acute necrotizing eosinophilic myocarditis in patients with relapsing polychondritis?
This case represents the first report of a TNF-α antagonist (adalimumab) potentially associated with fatal acute necrotizing eosinophilic myocarditis.
Clinicians should consider adalimumab in eosinophilic myocarditis differentials; hypothesis-generating for TNF-α antagonist causality.
Tumor necrosis factor α (TNF-α) antagonists are being increasingly used as maintenance therapies for rheumatic diseases, and therefore knowledge of their adverse effects is important. We report a case of fatal acute necrotizing eosinophilic myocarditis temporally related to use of a second course of the TNF-α antagonist, adalimumab. A 51-year-old woman with relapsing polychondritis took adalimumab 2 weeks before presenting with acute myocarditis. Within hours of presentation to the emergency department, she had cardiac arrest due to fulminant heart failure. Autopsy demonstrated necrotizing eosinophilic myocarditis. This is a rare cause of fulminant heart failure. This is the first report of a TNF-α antagonist potentially associated with acute necrotizing eosinophilic myocarditis.
No takes yet. Share an insight, caveat, or question.
Adamson et al. (2013) conducted a case report in Relapsing polychondritis (n=1). Adalimumab was evaluated on Fatal acute necrotizing eosinophilic myocarditis. Adalimumab use was temporally associated with fatal acute necrotizing eosinophilic myocarditis in a 51-year-old woman with relapsing polychondritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: